All News

Overall Survival Results of I/O Combinations Differ Across Risk Groups of Metastatic RCC

July 22, 2021

The overall survival benefit of immunotherapy combinations compared with sunitinib for the treatment of patients with metastatic renal cell carcinoma who have favorable risk may differ from those who have intermediate or poor risk, according to a pooled analysis of frontline combination therapy conducted by the FDA.

FDA Approves Lenvatinib/Pembrolizumab for Select Patients With Advanced Endometrial Cancer

July 22, 2021

The FDA has approved the combination of lenvatinib and pembrolizumab for the treatment of patients with advanced endometrial cancer that is not microsatellite instability–high or mismatch repair deficient, who have disease progression following prior systemic treatment and who are not candidates for curative surgery or radiation.

Precise Management of EGFR exon 20-Positive Non–Small Cell Lung Cancer

July 21, 2021

Research shows that methods used to treat the wide epidermal growth factor receptor-positive population are often not successful for patients with specific biomarkers like EGFR exon 20 insertion mutations, highlighting an ongoing need for more targeted therapies.